不同给药途径地塞米松预防成人外周神经阻滞后反跳痛:系统综述与网状Meta分析
该系统综述与网状Meta分析纳入14项随机对照试验共1058例患者,比较静脉与神经周围地塞米松预防外周神经阻滞后反跳痛的效果。结果显示静脉地塞米松在降低反跳痛发生率方面排名最高(每1000人减少298例,OR 0.12,95%CrI 0.03-0.44,中等确定性证据),神经周围地塞米松次之(每1000人减少190例,OR 0.34,95%CrI 0.07-1.32,低确定性证据)。给药途径与反跳痛发生时间之间未见效应证据。
要点
- 静脉地塞米松在预防外周神经阻滞后反跳痛方面排名最高,中等确定性证据支持。
- 静脉地塞米松预期每1000人减少298例反跳痛,OR 0.12(95%CrI 0.03-0.44)。
- 神经周围地塞米松每1000人减少190例反跳痛,但证据确定性低。
核心结论
- 静脉地塞米松与降低外周神经阻滞后反跳痛发生率的高概率相关,基于中等确定性证据。
- 给药途径与反跳痛发生时间之间无效应证据。
- 未来需研究确定最佳剂量。
研究设计与样本
- 系统综述与网状Meta分析,检索随机对照试验。
- 纳入14项研究,共1058例患者。
- 比较静脉地塞米松与神经周围地塞米松作为外周神经阻滞辅助用药,对照组为共同比较者。
主要发现
- 主要结局为反跳痛发生率。
- 静脉地塞米松排名最高,预期每1000人减少298例反跳痛(OR 0.12,95%CrI 0.03-0.44;中等确定性证据)。
- 神经周围地塞米松次之,预期每1000人减少190例反跳痛(OR 0.34,95%CrI 0.07-1.32;低确定性证据)。
- 给药途径与反跳痛发生时间之间无效应证据。
关键数值与推荐
- 静脉地塞米松:OR 0.12(95%CrI 0.03-0.44),中等确定性证据。
- 神经周围地塞米松:OR 0.34(95%CrI 0.07-1.32),低确定性证据。
- 采用累积排名曲线下面积计算干预排名最高的可能性。
临床怎么用
- 成人手术患者外周神经阻滞时,可优先考虑静脉给予地塞米松以降低反跳痛发生率。
- 神经周围地塞米松可作为替代选择,但证据确定性较低。
局限性
- 神经周围地塞米松的证据确定性为低。
- 未来需研究确定最佳剂量。
以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。
原文
INTRODUCTION: Rebound pain, characterised by intense pain or discomfort as the effects of a peripheral nerve block diminish, remains a clinical problem. Peri-operative dexamethasone administration may reduce the incidence of rebound pain. This systematic and network meta-analysis aimed to determine the optimal route of dexamethasone administration for the prevention of rebound pain. METHODS: We searched databases for randomised controlled trials according to pre-determined criteria. We compared intravenous and perineural dexamethasone as an adjunct to peripheral nerve blocks, with the control group as a common comparator. The primary outcome was the incidence of rebound pain. The likelihood of an intervention ranking highest was calculated using the surface area under the cumulative ranking curve. RESULTS: In total, 14 studies with 1058 patients were included. When compared with the comparator group, we found that intravenous dexamethasone ranked the highest, with an anticipated effect of 298 fewer cases of rebound pain per 1000 people (odds ratio (OR) (95% credible interval (CrI) 0.12 (0.03-0.44)); moderate certainty evidence). This was followed by perineural dexamethasone with an anticipated effect of 190 fewer cases per 1000 people (OR (95%CrI) 0.34 (0.07-1.32); low certainty evidence). There was no evidence of an effect between the route of administration and time to onset of rebound pain. DISCUSSION: Intravenous dexamethasone was associated with a high probability of decreasing the incidence of rebound pain following peripheral nerve block. This is based on moderate certainty of evidence. Future studies on identifying the optimal dose are now warranted.
引用
- Makkar JK, Singh NP, Khurana BJK, et al. Efficacy of different routes of dexamethasone administration for preventing rebound pain following peripheral nerve blocks in adult surgical patients: a systematic review and network meta-analysis. Anaesthesia. 2025. PMID: 39929722. doi:10.1111/anae.16566
供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。